Updated Seroprevalence of Hepatitis B Surface Antigen and Anti-Hepatitis Core Antibody Among Blood Donors in Yemen
Talal Alhazari,Jerold C Alcantara,Saleh A Majed,Abdulrahman S Bazaid,Abdu Aldarhami,Tawfique KA Alzubiery
DOI: https://doi.org/10.2147/IDR.S357819
2022-06-01
Infection and Drug Resistance
Abstract:Tawfique KA Alzubiery, 1 Talal Alhazari, 2, 3 Jerold C Alcantara, 2 Saleh A Majed, 4 Abdulrahman S Bazaid, 2 Abdu Aldarhami 5 1 Department of Medical Laboratory, Faculty of Medical and Health Sciences, Taiz University Al-Turbah Branch, Taiz, Yemen; 2 Department of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, Hail, Saudi Arabia; 3 Department of Medical Microbiology and Immunology, Faculty of Medicine and Health Sciences, Taiz University, Taiz, Yemen; 4 National Blood Transfusion and Research Center, Sana'a, Yemen; 5 Department of Medical Microbiology, Qunfudah Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia Correspondence: Talal Alhazari, Department of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, Hail, Saudi Arabia, Tel +966 531036805, Email Purpose: Hepatitis B virus (HBV) is one of the most common infectious pathogens worldwide. Various studies found a prevalence of HBV infection among blood donors ranging from 2% to 18%. Hence, this study aimed to provide an updated prevalence of HBsAg and anti-HBcAb among blood donors. Patients and Methods: This was a cross-sectional study to investigate the donation records of blood donors in Sana'a, Yemen, over one year (January to December 2019). Eligible blood donors were included in the study. The serum samples of blood donors were tested for HBsAg and anti-HBcAb (IgG & IgM) using the electrochemiluminescence (ECL) and enzyme immunoassay (EIA) techniques. Results: A total of 16,367 blood donors were recruited in this study, of whom 14,300 (87.4%) donated only once during this study (single, non-duplicated blood donors), while 2067 (12.6%) were repeated or duplicated. The overall prevalence of HBsAg and anti-HBcAb was 2.4% and 10.8%, respectively. Among single non-duplicated blood donors, HBsAg and Anti-HBcAb were 2.3% and 10.6% and 3.0% and 12.5% for repeated blood donors, respectively. There were statistically significant differences between HBsAg and Anti-HBcAb in terms of donor type and testing techniques. Conclusion: The seroprevalence of HBsAg and anti-HBcAb among the blood donors was 2.0% and 10.3%, respectively. The ECL technique is more sensitive, has a lower error rate, and shows an advantage over the manual EIA technique. Duplicated blood donors influence the accuracy of the seroprevalence of HBsAg and anti-HBcAb. Keywords: hepatitis infections, serological markers, transfusion transmissible infections, blood transfusion, Yemen The World Health Organization (WHO) Global Database on Blood Safety estimates over 92 million blood donations annually. 1 However, blood transfusion is not entirely free from the risk of transmission of infectious agents, such as Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Treponema pallidum, and malarial parasites. 1 Due to infectious agents such as HIV, HBV, HCV, and syphilis, about 1.6 million units are discarded. 2 WHO has recommended that pathogens causing transfusion-transmissible infections (TTIs) must be tested on all blood collected from blood donors. 1 HBV has infected over 2 billion people, with 360 million having chronic HBV infections and 3.0 million new infections per year. 3,4 Furthermore, over 1.1 million deaths per year are associated with HBV infections, and is the fifth leading cause of cancer in the world. 5,6 Several studies reported different rates of HBsAg in blood donors, from 1.2%, 1.4%, and 2.3% in Saudi Arabia, 9 Jordan 7 and Iraq, 8 to 4.3%, 5.1%, and 5.62% in Sudan, 10 Syria, 11 and Egypt, 12 respectively. In Yemen, the prevalence of HBV infection among blood donors ranges from 2% to 18%, as documented by many studies, where Yemen consequently falls into the intermediate to high endemicity category. 13–15 Previous studies revealed different results regarding viral hepatitis and HIV prevalence among blood donors. 14,16 It was noted that there was a discrepancy in the results, necessitating more investigation to improve and understand these variations and their impact. Hence, the purpose of this study was to update the prevalence rate of HBsAg and anti-HBc among blood donors and determine the reliability of using chemiluminescence and ELISA techniques as well as identifying the effect of duplicated or repeated blood donations on the results. The study is a prospective, cross-sectional design from January 2019 to December 2019. Serological testing of donor samples was done in the Virology laboratory. This study was conduct -Abstract Truncated-
pharmacology & pharmacy,infectious diseases